Related Experiment Video
Updated: Aug 13, 2026
09:14
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Advances and challenges in experimental models for Epstein-Barr virus research
Gulimire Wufuer1,2, Jiabao Tang1,2, Tingdong Li1,2
1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health Xiamen University Xiamen China.
Mlife
|August 12, 2026
Summary
Epstein-Barr virus (EBV) research relies on experimental models, from 2D cell lines to advanced 3D and animal models. Current models offer insights but require further innovation for comprehensive EBV pathogenesis and therapeutic development.
Area of Science:
- Virology
- Oncology
- Immunology
Background:
- Epstein-Barr virus (EBV) is a human oncovirus linked to various cancers and autoimmune diseases.
- Understanding EBV pathogenesis and developing treatments necessitates robust experimental models.
- Existing models, including 2D cell lines, 3D cultures, and animal models, have limitations in fully recapitulating disease complexity.
Purpose of the Study:
- To systematically review and analyze current experimental models for studying Epstein-Barr virus (EBV).
- To evaluate the technical features, applicability, and limitations of various in vitro and in vivo models.
- To provide guidance on selecting appropriate models and highlight the need for advanced, patient-specific platforms for EBV research.
Main Methods:
- Systematic review of literature on EBV experimental models.
- Analysis of 2D cell lines (e.g., LCLs, NPC43), 3D models (ALI cultures, spheroids, PDOs), and animal models (humanized mice, rabbits, tree shrews).
- Comparative assessment of model capabilities in mimicking viral latency, oncogenesis, immune responses, and disease progression.
Main Results:
- Traditional 2D models offer basic insights but lack physiological complexity.
- Emerging 3D models better mimic tissue environments but face scalability and immune integration challenges.
- Animal models recapitulate systemic interactions and immune responses but have species-specific constraints and incomplete TME representation.
Conclusions:
- No single model fully captures EBV's complex pathogenesis.
- Current models provide valuable but incomplete understanding, necessitating further development.
- Innovative, patient-tailored platforms are crucial for advancing EBV research, vaccine development, and therapeutic strategies.
